Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2013 pubmed 24 citations

Kisspeptin antagonists.

Roseweir. Antonia Kathryn AK; Millar. Robert P RP

Key Findings

  • Kisspeptin is a key regulator of the hypothalamic‑pituitary‑gonadal axis.
  • Blocking kisspeptin (antagonists) may treat hormone‑dependent reproductive disorders.
  • Four peptide antagonists and one small‑molecule antagonist have been designed so far.

Practical Outcomes

  • At present there’s no actionable protocol for biohackers; the work is mainly pre‑clinical and aimed at future medicines. Keep an eye on this area as it could lead to new hormone‑modulating drugs, but it isn’t ready for self‑experimentation.

Summary

Kisspeptin is a hormone that controls the reproductive system, and scientists are creating molecules that block it. These blockers could someday help treat conditions like early puberty, endometriosis, or prostate cancer, but they are still in early research stages and not ready for personal use.

Abstract

Kisspeptin is now known to be an important regulator of the hypothalamic--pituitary-gonadal axis and is the target of a range of regulators, such as steroid hormone feedback, nutritional and metabolic regulation. Kisspeptin binds to its cognate receptor, KISS1R (also called GPR54), on GnRH neurons and stimulates their activity, which in turn provides an obligatory signal for GnRH secretion-thus gating down-stream events supporting reproduction. The development of peripherally active kisspeptin antagonists could offer a unique therapeutic agent for treating hormone-dependent disorders of reproduction, including precocious puberty, endometriosis, and metastatic prostate cancer. The following chapter discusses the advances made in the search for both peptide and small molecule kisspeptin antagonists and their use in delineating the role of kisspeptin within the reproductive system. To date, four peptide antagonists and one small molecule antagonist have been designed.

Study Information

Provider

pubmed

Year

2013

DOI

10.1007/978-1-4614-6199-9_8

Citations

24